Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis

被引：0
|
作者：
Jun Ho Ji
Se Hoon Park
Jeeyun Lee
Tae Won Kim
Yong Sang Hong
Kyu-pyo Kim
Sun Young Kim
Ji Yeon Baek
Hye Jin Kang
Sang Joon Shin
Byoung Yong Shim
Young Suk Park
机构：
[1] Sungkyunkwan University School of Medicine,Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center
[2] University of Ulsan College of Medi cine,Department of Oncology, Asan Medical Center
[3] Center for Colorectal Cancer,Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital
[4] National Cancer Center,Department of Internal Medicine, Cancer Metastasis Research Centre, Yonsei Cancer Centre
[5] Korea Institute of Radiological and Medical Sciences,Medical Oncology Division, St. Vincent’s Hospital
[6] Yonsei University College of Medicine,Division of Hemato
[7] Catholic University of Korea,Oncology, Department of Medicine, Samsung Changwon Hospital
[8] Sungkyunkwan University School of Medicine,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2013年 / 72卷
关键词：
Colorectal cancer; Liver metastasis; Neoadjuvant; FOLFOX6; Cetuximab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：223 / 230
页数：7
相关论文
共 50 条
  • [21] The use of oral capecitabine with irinotecan and cetuximab (mCAPIRI-C) among colorectal cancer patients with unresectable liver-only metastases
    Wong, S.
    Chiang, C.
    Yeung, S.
    Lee, S.
    Lee, A.
    Wong, C.
    ANNALS OF ONCOLOGY, 2019, 30 : 58 - 58
  • [22] Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer
    Elez, E.
    Hendlisz, A.
    Delaunoit, T.
    Sastre, J.
    Cervantes, A.
    Varea, R.
    Chao, G.
    Wallin, J.
    Tabernero, J.
    BRITISH JOURNAL OF CANCER, 2016, 114 (04) : 372 - 380
  • [23] Phase I Study of Sunitinib plus Modified FOLFOX6 in Japanese Patients with Treatment-naive Colorectal Cancer
    Yoshino, Takayuki
    Yamazaki, Kentaro
    Hamaguchi, Tetsuya
    Shimada, Yasuhiro
    Kato, Ken
    Yasui, Hirofumi
    Boku, Narikazu
    Lechuga, Maria Jose
    Hirohashi, Tomoko
    Shbata, Atsushi
    Hashigaki, Satoshi
    Li, Yinhua
    Ohtsu, Atsushi
    ANTICANCER RESEARCH, 2012, 32 (03) : 973 - 979
  • [24] A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer
    Xiang Wang
    Lin Zhao
    Hongfeng Liu
    Dingrong Zhong
    Wei Liu
    Guangliang Shan
    Fen Dong
    Weisheng Gao
    Chunmei Bai
    Xiaoyi Li
    British Journal of Cancer, 2016, 114 : 1326 - 1333
  • [25] Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer
    E Elez
    A Hendlisz
    T Delaunoit
    J Sastre
    A Cervantes
    R Varea
    G Chao
    J Wallin
    J Tabernero
    British Journal of Cancer, 2016, 114 : 372 - 380
  • [26] A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer
    Wang, Xiang
    Zhao, Lin
    Liu, Hongfeng
    Zhong, Dingrong
    Liu, Wei
    Shan, Guangliang
    Dong, Fen
    Gao, Weisheng
    Bai, Chunmei
    Li, Xiaoyi
    BRITISH JOURNAL OF CANCER, 2016, 114 (12) : 1326 - 1333
  • [27] A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study
    Matsumura, Masaru
    Hasegawa, Kiyoshi
    Oba, Masaru
    Yamaguchi, Kensei
    Uetake, Hiroyuki
    Yoshino, Takayuki
    Morita, Satoshi
    Takahashi, Keiichi
    Unno, Michiaki
    Shimada, Yasuhiro
    Muro, Kei
    Matsuhashi, Nobuhisa
    Mori, Masaki
    Baba, Hideo
    Shimada, Mitsuo
    Mise, Yoshihiro
    Kawaguchi, Yoshikuni
    Kagimura, Tatsuo
    Ishigure, Kiyoshi
    Saiura, Akio
    Sugihara, Kenichi
    Kokudo, Norihiro
    LANGENBECKS ARCHIVES OF SURGERY, 2022, 407 (04) : 1345 - 1356
  • [28] A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study
    Masaru Matsumura
    Kiyoshi Hasegawa
    Masaru Oba
    Kensei Yamaguchi
    Hiroyuki Uetake
    Takayuki Yoshino
    Satoshi Morita
    Keiichi Takahashi
    Michiaki Unno
    Yasuhiro Shimada
    Kei Muro
    Nobuhisa Matsuhashi
    Masaki Mori
    Hideo Baba
    Mitsuo Shimada
    Yoshihiro Mise
    Yoshikuni Kawaguchi
    Tatsuo Kagimura
    Kiyoshi Ishigure
    Akio Saiura
    Kenichi Sugihara
    Norihiro Kokudo
    Langenbeck's Archives of Surgery, 2022, 407 : 1345 - 1356
  • [29] Modified FOLFOX6 and Bevacizumab As Neoadjuvant Chemotherapy for Patients With Potentially Curable Bilobar Liver Metastases From Colorectal Cancer
    Maeda, Atsuyuki
    Isogai, Masatoshi
    Kaneoka, Yuji
    GASTROENTEROLOGY, 2013, 144 (05) : S1079 - S1079
  • [30] A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
    Wainberg, Zev A.
    Messersmith, Wells A.
    Peddi, Parvin F.
    Kapp, Amy V.
    Ashkenazi, Avi
    Royer-Joo, Stephanie
    Portera, Chia C.
    Kozloff, Mark F.
    CLINICAL COLORECTAL CANCER, 2013, 12 (04) : 248 - 254
12345